Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BMS-986365 with Itraconazole and Rifampin in Healthy Male Participants
NCT07242781Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986365 in prostate cancer (PCa) (5 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Dec 2025; status: terminated.
02
Drugs
BMS-986365
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07242781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242781.